{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:53:27Z","timestamp":1782762807003,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,2,13]],"date-time":"2013-02-13T00:00:00Z","timestamp":1360713600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00280-013-2091-3","type":"journal-article","created":{"date-parts":[[2013,2,12]],"date-time":"2013-02-12T04:25:32Z","timestamp":1360643132000},"page":"981-990","source":"Crossref","is-referenced-by-count":36,"title":["A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas"],"prefix":"10.1007","volume":"71","author":[{"given":"Sook Ryun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Speranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Piekarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kinders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane B.","family":"Trepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Alarcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaani","family":"Kummar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,13]]},"reference":[{"key":"2091_CR1","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1124\/dmd.110.032151","volume":"38","author":"DJ Sweeny","year":"2010","unstructured":"Sweeny DJ, Li W, Clough J, Bhamidipati S, Singh R, Park G, Baluom M, Grossbard E, Lau DT (2010) Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos Biol Fate Chem 38:1166\u20131176","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"2091_CR2","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","volume":"319","author":"S Braselmann","year":"2006","unstructured":"Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES (2006) R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319:998\u20131008","journal-title":"J Pharmacol Exp Ther"},{"key":"2091_CR3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/bdra.20505","volume":"85","author":"GR Clemens","year":"2009","unstructured":"Clemens GR, Schroeder RE, Magness SH, Weaver EV, Lech JW, Taylor VC, Masuda ES, Baluom M, Grossbard EB (2009) Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Res A Clin Mol Teratol 85:130\u2013136","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"2091_CR4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/jpet.111.186429","volume":"340","author":"X Wang","year":"2012","unstructured":"Wang X, Mychajlowycz M, Lau C, Gutierrez C, Scott JA, Chow CW (2012) Spleen tyrosine kinase mediates BEAS-2B cell migration and proliferation and human rhinovirus-induced expression of vascular endothelial growth factor and interleukin-8. J Pharmacol Exp Ther 340:277\u2013285","journal-title":"J Pharmacol Exp Ther"},{"key":"2091_CR5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/leu.2011.248","volume":"26","author":"S Fruchon","year":"2012","unstructured":"Fruchon S, Kheirallah S, Al Saati T, Ysebaert L, Laurent C, Leseux L, Fournie JJ, Laurent G, Bezombes C (2012) Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis. Leukemia 26:795\u2013805","journal-title":"Leukemia"},{"key":"2091_CR6","unstructured":"Alley M, Hollingshead M, Pacula-Cox C, Carter J, Jacob W, Pine P (2008) Preclinical pharmacologic evaluations of R406\/R788, a multi-kinase inhibitor which exhibits unique, differential in vitro anticancer activity as well as in vivo antitumor efficacy following oral adminstration. In: American Association for Cancer Research Meeting. April 12\u201316, 2008, San Diego, Abstract 4889"},{"key":"2091_CR7","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115:2578\u20132585","journal-title":"Blood"},{"key":"2091_CR8","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2008-07-166439","volume":"113","author":"A Podolanczuk","year":"2009","unstructured":"Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB (2009) Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 113:3154\u20133160","journal-title":"Blood"},{"key":"2091_CR9","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/art.23992","volume":"58","author":"ME Weinblatt","year":"2008","unstructured":"Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E (2008) Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthr Rheum 58:3309\u20133318","journal-title":"Arthr Rheum"},{"key":"2091_CR10","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","volume":"363","author":"ME Weinblatt","year":"2010","unstructured":"Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB (2010) An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 363:1303\u20131312","journal-title":"N Engl J Med"},{"key":"2091_CR11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"2091_CR12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ejca.2010.12.016","volume":"47","author":"S Kummar","year":"2011","unstructured":"Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR, Juwara L, Cao L, Yu Y, Kim YS, Trepel J, Chen H, Choyke P, Melillo G, Murgo AJ, Collins J, Doroshow JH (2011) Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer 47:997\u20131005","journal-title":"Eur J Cancer"},{"key":"2091_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 10:1\u201310","journal-title":"Controlled Clin Trials"},{"key":"2091_CR14","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/0091270010381496","volume":"51","author":"M Baluom","year":"2011","unstructured":"Baluom M, Samara E, Grossbard EB, Lau DT (2011) Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Clin Pharmacol 51:1310\u20131318","journal-title":"J Clin Pharmacol"},{"key":"2091_CR15","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bbamcr.2009.03.004","volume":"1793","author":"RL Geahlen","year":"2009","unstructured":"Geahlen RL (2009) Syk and pTyr\u2019d: signaling through the B cell antigen receptor. Biochim Biophys Acta 1793:1115\u20131127","journal-title":"Biochim Biophys Acta"},{"key":"2091_CR16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/08916930903374717","volume":"43","author":"D Ghosh","year":"2010","unstructured":"Ghosh D, Tsokos GC (2010) Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases. Autoimmunity 43:48\u201355","journal-title":"Autoimmunity"},{"key":"2091_CR17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.critrevonc.2008.06.009","volume":"69","author":"B Dome","year":"2009","unstructured":"Dome B, Timar J, Ladanyi A, Paku S, Renyi-Vamos F, Klepetko W, Lang G, Dome P, Bogos K, Tovari J (2009) Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: from biology to therapy. Crit Rev Oncol Hematol 69:108\u2013124","journal-title":"Crit Rev Oncol Hematol"},{"key":"2091_CR18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12015-008-9028-y","volume":"4","author":"S Ergun","year":"2008","unstructured":"Ergun S, Hohn HP, Kilic N, Singer BB, Tilki D (2008) Endothelial and hematopoietic progenitor cells (EPCs and HPCs): hand in hand fate determining partners for cancer cells. Stem Cell Rev 4:169\u2013177","journal-title":"Stem Cell Rev"},{"key":"2091_CR19","first-page":"101","volume":"7","author":"Y Shaked","year":"2005","unstructured":"Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D\u2019Amato RJ, Kerbel RS (2005) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7:101\u2013111","journal-title":"Cancer Cell"},{"key":"2091_CR20","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1126\/science.1127592","volume":"313","author":"Y Shaked","year":"2006","unstructured":"Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785\u20131787","journal-title":"Science"},{"key":"2091_CR21","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","volume":"26","author":"S Dellapasqua","year":"2008","unstructured":"Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26:4899\u20134905","journal-title":"J Clin Oncol"},{"key":"2091_CR22","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/annonc\/mdq261","volume":"21","author":"M Ronzoni","year":"2010","unstructured":"Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, Bencardino K, Rovati B, Tinelli C, Falcone A, Villa E, Danova M (2010) Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol 21:2382\u20132389","journal-title":"Ann Oncol"},{"key":"2091_CR23","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/sj.bjc.6604741","volume":"99","author":"R Torrisi","year":"2008","unstructured":"Torrisi R, Bagnardi V, Cardillo A, Bertolini F, Scarano E, Orlando L, Mancuso P, Luini A, Calleri A, Viale G, Goldhirsch A, Colleoni M (2008) Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and\/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 99:1564\u20131571","journal-title":"Br J Cancer"},{"key":"2091_CR24","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2008.21.1771","volume":"27","author":"CG Willett","year":"2009","unstructured":"Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27:3020\u20133026","journal-title":"J Clin Oncol"},{"key":"2091_CR25","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1200\/JCO.2008.20.9908","volume":"27","author":"AX Zhu","year":"2009","unstructured":"Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27:3027\u20133035","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2091-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2091-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2091-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:11:27Z","timestamp":1559023887000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2091-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,13]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["2091"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2091-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,13]]}}}